MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure ...

Venous leg ulcers affect about 2% of individuals aged 65 and older, with over 1.5 million new cases reported annually in the U.S., the company said. They typically develop on the lower extremities ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

Skin Integrity Team has been shortlisted in three categories at this year’s Journal of Wound Care Awards, which take place ...

Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) is projected to release its earnings data after the market closes on Tuesday, February 18th. Analysts expect Tactile Systems Technology to ...

MediWound (NASDAQ:MDWD) stock climbed 4% following news that the company has initiated a Phase 3 study of its wound care product EscharEX in the treatment of venous leg ulcers, or VLU. The company ...

The addition of Marion General means the Lifeline of Ohio Placenta Donation Program will be available at all OhioHealth ...